Lexicon Pharmaceuticals Nachrichten und Aktivitäten
Präsenz
Lexicon Pharmaceuticals ist einer der ...
Lexicon Pharmaceuticals ist ein Unternehmen, das unter dem Börsenticker LXRX (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 25 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Lexicon Pharmaceuticals
- Mike Exton, Chief Executive Officer and Director
- Raymond Debbane, Chairman of the Board
- Diane Sullivan, Director
Letzte Veränderungen der Führungskräfte auf Lexicon Pharmaceuticals
- Dixon Terry, Vice President, Compliance, hat das Unternehmen verlassen (Nachrichten veröffentlicht am 21, Mai 2025).
- Scott Coiante, wurde beim Unternehmen als Chief Financial Officer eingestellt (Nachrichten veröffentlicht am 2, Januar 2025).
- Robert Lefkowitz, Director, geht in den Ruhestand (Nachrichten veröffentlicht am 21, November 2024).
Weitere Informationen zu den Änderungen auf Lexicon Pharmaceuticals
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Lexicon Pharmaceuticals nachzuverfolgen.
Biotechnologie
Lexicon Pharmaceuticals hat 2.350 Konkurrenten , einschließlich Astellas Gene Therapies (USA), Eurofins (Luxemburg) und Lonza (Schweiz).
Popular M&A news in Biotechnologie
- Sirius Therapeutics hat gerade eine Spendenaktion von 50 Millionen Dollar angekündigt. (veröffentlicht am 16, Juni 2025).
- BioNTech has announced the acquisition of CureVac (veröffentlicht am 12, Juni 2025).
- SpliceBio hat gerade eine Spendenaktion von 135 Millionen Dollar angekündigt. (veröffentlicht am 11, Juni 2025).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Lexicon Pharmaceuticals
- Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
- New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
- Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
- New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
- Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
- Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
- Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
- Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
- Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
- View more press releases Close
Social media about Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals auf Wikipedia, Google News & Yahoo Finance
- Lexicon Pharmaceuticals auf LinkedIn, Twitter & YouTube
